Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Dianthus Therapeutics reported Q3 2025 revenue of $0.396 million, down from $2.17 million a year ago, and a net loss of $36.8 million, up from $25.2 million in Q3 2024135.
Operating expenses were $40.7 million in Q3, mainly driven by increased research and development (R&D) spending of $32.5 million for clinical trials and program advancement35.
The company strengthened its financial position with an estimated adjusted cash balance of ~$525 million after public offering and milestone payments, providing runway into 2028235.
Recent achievements include positive Phase 2 MaGic trial results for claseprubart (statistically significant MG-ADL and QMG scores at Week 13) and plans for a Phase 3 gMG trial in 2026 with two dosing arms23.
Dianthus announced an exclusive license agreement for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor, with Phase 1 healthy volunteer data expected in 2H 202623.
The company accelerated the interim responder analysis of its Phase 3 CIDP CAPTIVATE trial from 2H 2026 to Q2 202623.
Despite increased losses, Dianthus successfully raised $288.4 million via public offering, increasing total assets to $577.4 million5.
Management expressed confidence in funding operations and clinical development for at least the next twelve months, with continued focus on delivering first-line biologic therapies for severe autoimmune diseases25.
Sources:
1. https://www.marketscreener.com/news/dianthus-therapeutics-inc-reports-earnings-results-for-the-third-quarter-and-nine-months-ended-sep-ce7d5cddde8efe21
2. https://www.globenewswire.com/news-release/2025/11/05/3181899/0/en/Dianthus-Therapeutics-Highlights-Recent-Business-Achievements-and-Reports-Q3-Financial-Results.html
3. https://www.stocktitan.net/news/DNTH/dianthus-therapeutics-highlights-recent-business-achievements-and-zvfxa5p8dadg.html
5. https://www.tipranks.com/news/company-announcements/dianthus-therapeutics-reports-q3-2025-financial-results